Key Developments For BioScrip, Inc.
BioScrip, Inc. (BIOS.O) (Consolidated Issue listed on NASDAQ Global Market)
BioScrip Inc. Issues Q3 2009 Revenue Guidance Above Analysts' Estimates; Comments On O4 2009 Revenue Guidance-Conference Call
BioScrip Inc. announced that for the remainder of 2009, it expects a 2% to 3% sequential sales growth compared to the second quarter 2009. The Company reported revenue of $328.7 million for the second quarter 2009. According to Reuters Estimates, analysts were expecting the Company to report revenue of $327.2 million and $337.8 million for the third and fourth quarter of 2009 respectively.
BioScrip Inc. Commences Patient Enrollment In Teva Neuroscience Therapy Optimization In Multiple Sclerosis Research Study
BioScrip Inc. announced that Teva Neuroscience tapped BioScrip Specialty Pharmacy as one of several national research study participants in MS research studies. TOP MS is a new research study for MS patients. The study will collect information, through online surveys about the quality of life, symptoms, relapse, employment, usual level of activity participation and general health activity from individuals living with MS for a two-year period.
BioScrip Inc. Reiterates FY 2009 Revenue Outlook
BioScrip Inc. reiterated its fiscal 2009 outlook and expects revenue growth, without CAP and United, in the range of 10%-15%. According to Reuters Estimates, analysts were expecting the Company to report revenues of $1.352 billion for the same period.
BioScrip Inc. Appoints Richard Smith As President
BioScrip Inc. announced that Richard M. Smith has been appointed as its President and Chief Operating Officer. Mr. Smith will begin work on or before January 2, 2009, after a short transition period with his current employer.
BioScrip Inc. Issues Q4 2008 Revenue Outlook Above Analysts' Estimates-Conference Call
BioScrip Inc. announced that for the fourth quarter of 2008, it expects sales to increase 2% to 3% over the third quarter. The Company reported revenue of $359.43 million in the third quarter of 2008. According to Reuters Estimates, analysts were expecting the Company to report revenue of $359 million for the fourth quarter of 2008.
